Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...

Eli Lilly’s (NYSE: LLY) latest acquisition has electrified the biotech world—and sent a clear message that gene editing is no longer just for rare diseases. The US pharma major is paying $1 billion ...

Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results Provided by GlobeNewswire Feb 27, 2025, 12:00:00 PM ...

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for ...